Comparison of 4, 8, and 12 week screening and foot care frequencies in persons in remission: The DIATIME comparative efficacy study – A randomized clinical trial
Loading...
Official URL
Full text at PDC
Publication date
2025
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citation
López-Moral M, García-Madrid M, García-Morales E, García-Álvarez Y, Álvaro-Afonso FJ, Lázaro-Martínez JL. Comparison of 4, 8, and 12 week screening and foot care frequencies in persons in remission: The DIATIME comparative efficacy study - A randomized clinical trial. Diabetes Res Clin Pract. 2025 Dec;230:112962. doi: 10.1016/j.diabres.2025.112962. Epub 2025 Oct 24. PMID: 41139025.
Abstract
Aims
This study aimed to evaluate the clinical efficacy of 1, 2, and 3 months-based screening periods for the prevention of plantar DFUs in patients in remission.
Methods
A randomized, three-arm, controlled trial was conducted in 148 patients at high – risk in remission with a healed plantar foot ulcer. For the three treatment groups, the procedures were the same; the only difference was the screening timeframe: group 1, 4 weeks; group 2, 8 weeks; and group 3, 12 weeks. Primary outcome measure was the percentage of participants with plantar recurrence by the 1-year follow-up period.
Results
During the 12-month follow-up period, 50 participants (33.8 %) experienced a recurrence. We observed that participants in the 12-weeks group experience DFU recurrence significantly more frequently (n = 27, 46 %) than the 4-weeks (n = 18, 18.4 %) and 8-weeks (n = 14, 28.6 %) groups (P < 0.001). Ulcer survival curves significantly differed between the study groups (log-rank test, P < 0.001). In the logistic regression model, allocation was the only variable associated with ulcer recurrence during the 1-year follow-up period (P < 0.001, 95 % confidence interval:1.509–4.001).
Conclusions
This trial found superior clinical efficacy in preventing plantar recurrence rates with the 4-weeks screening period compared to 8 and 12 weeks.
This trial was registered at Clinicaltrials.gov (identifier ID NCT06143215) within the Unique Protocol ID name of the Diatime randomized controlled clinical trial.
Description
APC financiada por la UCM: para los acuerdos transformativos de la CRUE











